Use, accuracy, and implications for patient management of [18F]-2-fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors

Laryngoscope. 2005 Jul;115(7):1186-90. doi: 10.1097/01.MLG.0000163763.89647.9F.

Abstract

Objectives/hypothesis: Positron emission tomography (PET) has shown promise for early detection and accurate staging of cancer patients. A limited number of studies suggest PET/computed tomography (CT) may improve these variables; however, no published study has specifically evaluated clinical outcomes with PET/CT for head and neck (HN) tumors. The current study evaluates the use, accuracy, and implications for patient management of PET/CT scans in patients with HN tumors.

Study design: Retrospective cohort outcomes study at a tertiary care center.

Methods: The authors identified 795 consecutive PET/CT at our institution. A total of 113 were obtained for HN tumors; 97 were used in the final analysis. Accuracy, use, and implications for patient care management decisions were correlated with each PET/CT scan. Multiple regression analysis was performed.

Results: Accuracy, sensitivity, and specificity were measured by comparing the PET/CT results at the primary tumor site, cervical node sites, and distant sites with either pathologic or definitive clinical diagnoses. PET/CT had an overall per scan accuracy of 72% and a per patient accuracy of 69%. When stratification for rationale of obtaining the scan was performed, accuracy was 80% for staging distant disease, 67% for primary tumor evaluation, 72% for evaluation for recurrence, and 60% for unknown primary tumor evaluation.

Conclusions: PET/CT imaging is a promising tool for evaluating HN tumors; however, in clinical practice, the proper use of such technology is not well studied. In our study, PET/CT had an overall accuracy of 72% in evaluating HN tumors, and PET/CT had the most accuracy in the detection of distant metastasis.

Publication types

  • Validation Study

MeSH terms

  • Brain / blood supply
  • Brain / diagnostic imaging
  • Brain / metabolism
  • Cohort Studies
  • Diagnosis, Differential
  • Female
  • Fluorodeoxyglucose F18* / pharmacokinetics
  • Head and Neck Neoplasms / diagnostic imaging*
  • Head and Neck Neoplasms / metabolism
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Positron-Emission Tomography*
  • Radiopharmaceuticals* / pharmacokinetics
  • Regression Analysis
  • Reproducibility of Results
  • Retrospective Studies
  • Sensitivity and Specificity
  • Tomography, X-Ray Computed*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18